Inclusion Criteria:

- Provide written informed consent and HIPAA authorization for the release of personal
health information.

- Adult male ≥18 years of age

- No desire to drink any alcohol during the study period. (The potential for ethanol
interactions may last 7 to 14 days. Patient is allowed to drink alcohol 2 weeks after
the study is finished)

- Histological confirmed diagnosis of adenocarcinoma of the prostate (M0) with evidence
of biochemical relapse after local therapy (i.e., surgery, radiation therapy, or
both). Baseline PSA must be ≥ 1 ng/ml.

- There must be a confirmed rise in PSA shown by 2 PSA values at least 1 week apart,
higher than a reference value noted within 12 months of study entry. Interim PSA
values during the immediate pre-study 12-month interval may demonstrate a
"fluctuation" including a decline; however the study baseline PSA must have show a
rise within the pre-study 12-months period. Baseline PSA must be determined within 4
weeks of study entry. At least 3 PSA values are necessary to calculate PSA doubling
time via PSADT calculator.

- All previous local modalities of treatment, including radiation and surgery, must
have been discontinued at least 4 weeks prior to treatment in this study. Patients
may have received prior systemic chemotherapy, hormonal therapy, biologic or vaccine
therapy

- Patients receiving intermittent hormonal therapy for their rising PSA state are
considered eligible if testosterone level is above 150ng/dl and treatment was
discontinued > 6 months and agree not to have additional injections while on study
drug.

- No history of or current clinical or radiological evidence of distant metastases
(excluding prostascint scan/PET in absence of radiographic disease in Bone scan, CT
scan or MRI if used). Retroperitoneal/pelvic lymph node up to 2 cm size is allowed
for the study.

- ECOG performance score < 2 within 14 days before being registered for protocol
therapy

- Normal organ function with acceptable initial laboratory values:

- Absolute neutrophil count ≥ 1 x 109/L

- Platelets > 50 x 109/L

- Creatinine <2 mg/dL

- Bilirubin <1.5 X ULN (institutional upper limits of normal)

- AST (SGOT) and ALT (SGPT) ≤ 1.5 x ULN

- Willingness to use adequate methods of contraception throughout study
participation and for at least 3 months after completing therapy

Exclusion Criteria:

- Metastatic disease or currently active second malignancy

- History of alcohol dependence, seizures or psychoses.

- Medical conditions such as uncontrolled hypertension, uncontrolled diabetes mellitus,
cardiac disease, active infectious hepatitis, type A, B or C, hypothyroidism, which
would, in the opinion of the investigator, make this protocol unreasonably hazardous

- Major thoracic or abdominal surgery within the prior 3 weeks. Patients with GI tract
disease resulting in an inability to take oral medication, malabsorption syndrome, a
requirement for IV alimentation, prior surgical procedures affecting absorption,
uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).

- Use of any prohibited concomitant medications: Metronidazole, Amprenavir,
Paraldehyde, Phenytoin, Coumadin, alcohol or alcohol-containing preparations,
Isoniazid, Amitriptyline (please see Appendix B for other potential drug-drug
interactions). The washout period is at least 2 weeks before starting the study

- Insufficient time from last prior regimen or radiation exposure: Systemic therapies
for prostate cancer within 28 days prior to disulfiram; strontium-89 within 12 weeks;
bicalutamide within 6 weeks.

- Persistent Grade >2 treatment-related toxicity from prior therapy

- History of any disulfiram-related or drug induced anaphylactic reaction

- Receipt of another investigational agent within 28 days of study entry. Patient must
have recovered from all side effects of prior investigational therapy